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ABSTRACT 
Background:  
Radical hysterectomy with pelvic lymphadenectomy represents the standard treatment for early 
stage cervical cancer. Results from a recent randomized controlled trial demonstrate that 
minimally invasive surgery is inferior to laparotomy with regards to disease-free and overall 
survival. 
Primary objective: 
To investigate the oncologic safety of robot-assisted surgery for early stage cervical cancer as 
compared to standard laparotomy. 
Study hypothesis: 
Robot-assisted laparoscopic radical hysterectomy is non-inferior to laparotomy in regards to 
recurrence free survival with the advantage of less postoperative complications and superior 
patient reported outcomes. 
Trial design: 
Prospective, multi-institutional, international, open-label randomized clinical trial. Consecutive 
women with early stage cervical cancer will be assessed for eligibility and subsequently 
randomized 1:1 to either robot-assisted laparoscopic surgery or laparotomy. Institutional Review 
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Board approval will be required from all participating institutions. The trial is coordinated from 
Karolinska University Hospital, Sweden. 
Major inclusion/exclusion criteria: 
Women over 18 with cervical cancer FIGO (2018) stages IB1, IB2 and IIA1 squamous, 
adenocarcinoma, or adenosquamous will be included. Women are not eligible if they have 
evidence of metastatic disease, serious comorbidity or a secondary invasive neoplasm in the past 
five years. 
Primary endpoint: 
Recurrence-free survival at 5 years between women who underwent robot-assisted laparoscopic 
surgery versus laparotomy for early stage cervical cancer. 
Sample Size: 
The clinical non-inferiority margin is in this study defined as a 5-year recurrence-free survival 
not worsened by more than 7.5%. With an expected recurrence-free survival of 85%, the study 
needs to observe 127 events with a one-sided level of significance (α) of 5% and a power (1-β) 
of 80%. With 5 years of recruitment and 3 years of follow-up, the necessary number of events 
will be reached if the study can recruit a total of 768 patients. 
Estimated Dates for Completing Accrual and Presenting Results: 
Trial launch is estimated to May 2019 and is estimated to finally close in May 2027 with 
presentation of data short thereafter. 
  
 
5 
 
Trial registration: The trial is registered at ClinicalTrials.gov (NCT03719547) 
INTRODUCTION 
Cervical cancer has become a rare disease in the industrialized world but remains one of the most 
common cancers in developing countries.1 Radical hysterectomy with pelvic lymphadenectomy 
represents the standard of care for patients with early stage disease. The procedure can be 
performed either by laparotomy or minimally invasive techniques. Laparoscopic radical 
hysterectomy was first described in 1992 and is widely recognized as one of the most 
challenging surgical procedures in gynecologic oncology.2 In 2005, robot-assisted laparoscopic 
surgery was approved by the Food and Drug Agency for gynecological indications and the 
technique gained rapid popularity and has replaced conventional laparoscopy in many 
institutions. In the Nordic countries, laparoscopic radical hysterectomy never gained acceptance 
and in 2018, more than 80 % of radical hysterectomies were performed with robot-assisted 
laparoscopic surgery in Sweden. Several studies suggest that the learning curve is significantly 
shorter for robot-assisted laparoscopic surgery compared to conventional laparoscopy, which 
may be related to improved instrumentation in the robotic platform.3 In addition, retrospective 
analyses including two meta-analyses suggest that the oncologic safety is comparable between 
open surgery and robot-assisted laparoscopic surgery.4,5 However, results from a recent 
randomized trial have questioned the safety of minimally invasive surgery for cervical cancer. In 
the international LACC-trial, the final study population comprised 631 women with early stage 
cervical cancer, randomized to either open radical hysterectomy or minimally invasive surgery.6 
In the minimally invasive surgery group, the majority of women were operated by conventional 
laparoscopy (84 %) whereas only 16% of the women underwent robot-assisted laparoscopic 
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surgery. After a median follow-up of 30 months, minimally invasive surgery was inferior to 
laparotomy with a hazard ratio of 3.7 (95% CI 1.63-8.58) for recurrence and 6.0 (95% CI 1.77-
20.3) for overall survival. The authors speculate that the use of intrauterine manipulators, the 
CO2 gas or intra-corporeal colpotomy may account for the surprising outcomes. The results from 
the LACC-trial were in part supported by population-based data from the United States, 
demonstrating that minimally invasive surgery was associated with significantly worse survival 
outcomes than women treated by open access.7 In contrast to the LACC-trial, a majority of 
women in the minimally invasive group were operated with robot-assisted laparoscopic surgery.  
In Sweden, treatment of cervical cancer is centralized to seven university hospitals and data from 
all radical hysterectomies are entered into a national quality registry since 2011 (Swedish Quality 
Register for Gynecologic Cancer, SQRGC). Based on 822 cases of radical hysterectomies 2011-
2017, no difference in either disease-free survival or overall survival could be observed in the 
Swedish cohort (submitted for publication). Similar results have been obtained from the Danish 
quality register (personal communication). 
In summary, the LACC trial does not reflect current practice in many countries including the 
Nordic countries. The health care systems have gradually adopted robot-assisted laparoscopic 
surgery and the perceived safety is supported by data from Nordic population-based quality 
assurance databases. However, the LACC trial is currently the only randomized controlled trial 
exploring the oncologic safety of minimally invasive surgery and to establish the safety of 
current practice, a new randomized controlled trial is needed. Given the excellent outcomes in 
the open arm in the LACC trial, it is unlikely that robot-assisted laparoscopic surgery can 
generate superior outcomes. In the RACC-trial, we hypothesize that robot-assisted laparoscopic 
surgery is non-inferior to laparotomy but associated with less morbidity, shorter hospitalization 
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and superior patient reported quality of life. In addition, we will investigate if sentinel lymph 
node biopsy using indocyanine green as tracer, has sufficient diagnostic accuracy to replace 
conventional lymphadenectomy in women with early stage cervical cancer. 
 
METHODS 
Trial Design 
The RACC-trial is a prospective, international, multi-institutional, open-label randomized 
controlled trial. Figure 1 gives the study schema of the RACC-trial (Fig 1). Women with early 
stage cervical cancer will be assessed for eligibility and subsequently randomized 1:1 to either 
robot-assisted laparoscopic surgery or laparotomy. Informed consent is required from all 
participating women. The surgical procedure comprises total radical hysterectomy according to 
the Querleu-Morrow classification (type B or C) and pelvic lymphadenectomy.8 The use of intra-
uterine manipulators is not allowed, closure of the vagina prior to colpotomy is recommended 
but not mandatory. In addition, the sensitivity and negative predictive value of pelvic sentinel 
lymph node biopsy will be investigated using cervical injection of indocyanine green. To avoid 
any imbalance in the detection of low-volume disease based on ultrastaging between the arms, 
sampling (with subsequent ultrastaging) will be performed in non-mapped hemi-pelvises 
according to the most frequent sites of nodal metastases.9 Intraoperative complications will be 
classified according to Kaafarani et al and the CLASSIC classification.10,11 Postoperative 
complications are classified according to the Clavien-Dindo nomenclature.12 Patient Reported 
Outcomes will be assessed at baseline (prior to randomization), 1 month postop, 6 months 
postop, 1 year postop, 2 years postop and 5 years postop using four different instruments: the 
EORTC QLQ-C30, QLQ-CX24, EQ5D and LYMQOL. Objective assessment of lymphedema 
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will be performed using CTCAE 3.0. Finally, health care costs will be assessed for both 
modalities. 
To date, 16 sites from across Scandinavia and Germany are expected to participate in the RACC-
trial with the potential to add additional sites as needed. The trial is funded by Stockholm County 
Council (Sweden). 
Participants 
Inclusion Criteria: 
Histologically confirmed primary adenocarcinoma, squamous cell carcinoma or adeno-squamous 
carcinoma of the uterine cervix 
Women with histologically confirmed FIGO stage IB (IB3 excluded) and IIA1 (with minimally 
tumor growth in the upper vagina) 
Women undergoing either a Type B or C radical hysterectomy according to Querleu Morrow 
classification 
ECOG Performance Status of ≤2 
Age > 18 years 
Exclusion Criteria: 
Any histology other than adenocarcinoma, squamous cell carcinoma or adeno-squamous 
carcinoma of the uterine cervix 
Tumor size greater than 4 cm, estimated by either magnetic resonance imaging or clinical 
examination 
FIGO stage II-IV (except IIA1) 
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Women with a history of pelvic or abdominal radiotherapy 
Women who are pregnant 
Women with evidence of metastatic disease by conventional imaging studies, enlarged pelvic or 
aortic lymph nodes > 2cm; or histologically positive lymph nodes 
Serious concomitant systemic disorders incompatible with surgery (at the discretion of the 
investigator) 
Women unable to withstand prolonged lithotomy and steep Trendelenburg position 
Women with secondary invasive neoplasm in the past five years (except non-melanoma skin 
cancer, breast cancer T1 N0 M0 grade 1 or 2 without any signs of recurrence or activity) 
Women with iodine allergy cannot be part of the sentinel node part of the trial but are allowed 
randomization as to the primary outcome 
 
Primary endpoint 
Primary objective: 
This trial aims to compare the oncologic safety of robot-assisted laparoscopic surgery to standard 
laparotomy. Primary outcome measure: 5-year recurrence-free survival. 
 
Secondary Objectives:  
To evaluate overall survival, intra- and postoperative outcomes 30 days after surgery, health care 
costs, quality of life and lymphoedema and the diagnostic accuracy of pelvic sentinel lymph 
node biopsy in women with early stage cervical cancer. In addition, a translational part exploring 
biomarkers for disease recurrence is planned.  
10 
Quality assurance of participating centers and surgeons 
Participating centers: 
To ensure that quality standards are met, a site quality assessment form including institutional 
experience with robot-assisted laparoscopic surgery, annual volume of surgical gynecologic 
oncology cases and cervical cancer must be completed. In addition, 10 anonymous surgery 
reports from both radical hysterectomies and advanced ovarian cancer primary surgeries 
accompanied by their histopathology reports within 24 months, has to be sent to the trial steering 
committee for review. Moreover, surgical variables (e.g. operation time, blood loss) and 
complications within 30 days after surgery according to Clavien Dindo must be reported. 
Furthermore, the infrastructure to participate in the trial must be satisfactory and data on 
institutional algorithm and indication for adjuvant treatment and what it constitutes must be 
reported. The total annual case-load of robotic procedures per site must exceed 100. In addition, the 
institutions ability to perform pathologic ultrastaging is considered. 
For centers participating in the sentinel node part of the trial, on-site training can be arrange by 
the Trial Steering Committee if the methodology is not established. All removed tissue 
specimens must be reviewed by a gynecological oncology reference pathologist. Central 
pathology review will not be performed. 
During the study, it is at the discretion of the coordinating investigators and Trial steering 
committee to close centers with a higher than average rate of postoperative major complications 
from further accrual, temporarily of irrevocably after consultation with the Data Safety 
Monitoring Board. 
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Participating surgeons: 
All included surgeons outside the primary investigating center must be approved by the 
coordinating investigators. In the site identification and quality assessment form the participating 
surgeons experience and annual caseload will be reported for review. It is at the discretion of the 
coordinating investigators to select or deselect individual surgeons from participating in the trial. 
Audits on site or videos of procedures can be requested at the discretion of the coordinating 
investigators. Only surgeons stated in the Quality assessment form are allowed to be lead 
surgeons, amendments during the trial can be made.  
For robot-assisted laparoscopic surgery, all included surgeons must have a previous experience 
of at least 20 radical hysterectomies and pelvic lymphadenectomies. For laparotomy, all included 
surgeons must have a previous experience of at least 20 pelvic lymphadenectomies and an annual 
caseload of at least 10 surgeries for advanced pelvic surgery including pelvic lymphadenectomy. 
Previous experience of at least 10 open radical hysterectomies is mandatory.  
 
Sample size and interim analysis 
Sample size: 
The sample size is based on the hypothesis that robot-assisted laparoscopic surgery will not 
worsen recurrence-free survival at 5 years by more than a maximum of 7.5%. Assuming a 5-year 
recurrence-free survival of 85% for patients treated with standard treatment (radical 
hysterectomy and pelvic lymphadenectomy by laparotomy) this corresponds to a hazard rate of 
1.57. The chosen non-inferiority margin is based on the margin used in LACC-trial and other 
similar trials.  
To show that the 5-year recurrence-free survival in the robot-assisted laparoscopic surgery arm is 
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not worse than 77.5% compared to the expected 5-year rate of 85% in the standard arm, the 
study needs to observe 127 events with a one-sided level of significance (α) of 5% and a power 
(1-β) of 80%. It is estimated that with 5 years of recruitment and 3 years of follow-up, the 
necessary number of events will be reached if the study can recruit 768 patients. The non-
inferiority margin at 5-years correspond to a hazard ratio (HRRALS vs Standard) of 1.57. If, at the time 
of the statistical analysis, the upper two-sided 90% confidence interval – this corresponds to a 
one-sided test at the 5% level – falls below 1.57, non-inferiority will be concluded. 
The sample size is based on an observed recurrence-free survival of 85% from the Swedish 
Quality Register of Gynecologic Cancer 2011-2017. However, the sample size ultimately 
depends on the true recurrence-free survival in the RACC-trial. The following sensitivity 
analysis demonstrates the changes in sample size depending on true recurrence-free survival 
(Table 1). 
Table 1. Estimated sample size depending on true recurrence-free survival (RFS). 
Standard 
RFS 
HRNIM Experimental 
RFS 
Absolute 
NIM 
Total events 
(n) 
Total sample size 
(n) 
85% 1.568 77.5% 7.5% 127 768 
87.5% 1.671 80.0% 7.5% 97 712 
90% 1.826 82.5% 7.5% 72 656 
HR= Hazard ratio 
RFS=Recurrence-free survival 
NIM=Non-inferiority margin 
Interim analysis: 
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An independent safety and monitoring committee will review the data and carry out an interim 
analysis 3 years after the first patient is randomized or when 300 patients have been included in 
the study, whichever comes first. The purpose of this interim analysis is to assess the overall 
failure (recurrence/death) rate, to assess the recruitment to the study and to make sure that none 
of the treatment groups appear to fare worse than the other. 
Randomization 
After verification of eligibility, signed informed written consent and baseline Health Related 
Quality of Life questionnaires completed, patients will be randomized to either robot assisted 
laparoscopic surgery or laparotomy by equal allocation, 1:1. The randomization procedure will 
be pre-stratified for participating centers. Randomization will be performed centrally by the 
Clinical Trials Unit at Center for Clinical Cancer Studies, Theme Cancer, Karolinska University 
Hospital, Stockholm, Sweden. At the time of randomization, inclusion and exclusion criteria are 
entered into the randomization/registration application, which is a web-based instrument 
(ALEA). 
Statistical Methods 
The primary endpoint will be calculated from the date of randomization to the date of histology 
verified local recurrence, the date of distant recurrence or date of death (any cause), whichever 
comes first. For event-free patients, survival time will be calculated from the date randomization 
to the date of last clinical follow-up. 
Recurrence-free survival will be graphically displayed as Kaplan-Meier curves. 
Differences in survival times will be tested using a stratified (center) log-rank test. The effect of 
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treatment on time to failure will be estimated using a stratified (center) proportional hazards 
regression model. Results will be presented as a hazard ratio 13 together with a 90% confidence 
interval 9, which corresponds to the one-sided hypothesis. As this is the main endpoint in the 
study, a graph illustrating the estimated Hazard Ratio and 90% CI together with the non-
inferiority margin (Hazard Ratio=1.57) will also be presented. All analyses of recurrence-free 
survival will be performed according to the intention-to-treat principle but may also be presented 
as per-protocol. Ad hoc stratified analyses will be performed regarding tumor size. 
DISCUSSION 
The unexpected results presented from the LACC-trial have questioned the safety of minimally 
invasive surgery for cervical cancer.6 With an almost four times higher likelihood of disease 
recurrence, surgeons must now decide whether they should abandon minimally invasive surgery 
on this indication. As a minimum, patients must now be informed of the results from the LACC-
trial before a decision on surgical modality can be made. The results from the LACC-trial are 
also supported by data extracted from the Surveillance, Epidemiology, and End Results program, 
showing that survival after radical hysterectomy for cervical cancer decreased annually by 0.8 % 
after the introduction of robot-assisted laparoscopic surgery in 2005 in the United States.7 
The promise of improved patient outcomes after minimally invasive surgery have been supported 
by multiple, retrospective studies suggesting that several parameters including blood loss, 
complications and shorter hospitalization are superior after minimally invasive surgery compared 
to laparotomy.13-15 In addition, no reports prior to the LACC-trial have indicated that the 
oncologic safety is compromised after minimally invasive surgery for cervical cancer. Indeed, 
two large, international randomized controlled trials have demonstrated similar survival for 
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women with endometrial cancer after both open surgery and minimally invasive surgery.16,17 The 
confusion among surgeons is enhanced by the lack of plausible causes for the potentially worse 
outcomes after minimally invasive surgery for cervical cancer. Multiple reasons have been 
suggested including the use of intra-uterine manipulators, intra-abdominal dehumidification by 
the CO2-gas or intra-corporeal colpotomy with subsequent tumor spillage in the pelvis. 
However, none of these potential causes are supported by the literature and remain speculative. 
The timing of randomized controlled trials for procedural interventions is one of the most critical 
aspects to consider when a trial later is scrutinized.18 If the trial is conducted “too early”, type II 
errors may occur since procedures require maturation before they can be evaluated. Conversely, 
a randomized controlled trial initiated “too late” may lead to the perception among clinicians that 
the procedure has become standard of care. The most difficult parameter to assess in the context 
of oncologic outcomes is by no doubt surgical proficiency. In the LACC-trial, an attempt was 
made to secure high quality standards and all participating surgeons had to submit both edited 
and non-edited videos before they were allowed to enter the trial. However, assessing surgical 
proficiency is highly subjective since no objective quality standards for a radical hysterectomy 
exists. Most women in the minimally invasive surgery arm of the LACC-trial were operated by 
conventional laparoscopy and to a much lesser extent, robot-assisted laparoscopic surgery. The 
proportion of laparoscopic radical hysterectomy vs robot-assisted laparoscopic surgery reflects 
the timing of the trial and the latter had only been approved for gynecologic indications three 
years prior to the study initiation. It is therefore reasonable to assume that the robot-assisted 
laparoscopic surgery procedures in the LACC-trial were performed by early adopters in their 
early learning-curve. Laparoscopic radical hysterectomy is widely recognized as one of the most 
difficult surgical interventions in gynecologic oncology and has gradually been replaced by 
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robot-assisted laparoscopic surgery (or never implemented at all).  Most surgeons would most 
likely agree that robot-assisted laparoscopic surgery provides substantial benefits compared to 
conventional laparoscopy, including the ability to better use wrist movements by the improved 
dexterity in the robotic platform. This notion is supported by several studies demonstrating 
shorter learning-curve for robot-assisted laparoscopic surgery compared to conventional 
laparoscopy.3,19,20 Today, the majority of minimally invasive surgery radical hysterectomies are 
performed by robot-assisted laparoscopic surgery in Nordic countries. 
Following the alarming results from the LACC-trial, data from the Swedish Quality Register for 
Gynecologic Cancer has been extracted. Entering data in the Swedish Quality Register for 
Gynecologic Cancer is mandatory in Sweden and the nation-wide coverage exceeds 99% of all 
procedures. Based on 852 women treated 2011-2017, no difference was observed for disease-free 
survival between minimally invasive surgery (n=628) and laparotomy (n=263). It should be 
noted that all women in the former group were treated with robot-assisted laparoscopic surgery 
since laparoscopic radical hysterectomy has never gained acceptance in Sweden. Similar data 
have been obtained from the Danish Gynecological Cancer Database. Although non-randomized, 
the population-based data derived from these quality registers are in contrast with the results 
from the LACC-trial. To establish the safety of robot-assisted laparoscopic surgery, a new 
randomized controlled trial is needed. 
In summary, the international RACC-trial will evaluate whether robot-assisted laparoscopic 
surgery is a safe alternative to laparotomy for the treatment of early stage cervical cancer. In 
addition, the RACC-trial will assess whether conventional lymphadenectomy can be replaced by 
a sentinel-node biopsy concept using indocyanine green as the tracer. The trial is anticipated to 
start accrual in May 2019. 
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